View clinical trials related to Eye Diseases.
Filter by:The objective is to compare the USL and placebo in terms of efficacy and safety, and to determine the appropriate dosage.
The objective of this study is to evaluate the clinical efficacy of topical spironolactone ophthalmic solution, 0.005 mg/cc in subjects with dry eye disease compared to placebo. The hypothesis for this study is that topical spironolactone ophthalmic solution will be beneficial in the management of signs and symptoms of dry eye disease when compared to placebo.
This study intends to analyze the characteristics between peripapillary retinal nerve fiber layer thickness and peripapillary area in high myopia with or without glaucoma
This study aims to involve the public, patients and National Health Service (NHS) staff in co-designing a scalable, inclusive and sustainable implementation model for ophthalmic remote consultation with vision self-testing (the intervention). The main study questions are: What are the barriers to uptake of the intervention and how can these be mitigated by the design of the implementation model. How do implementation outcome measures compare before and after real world application of the model.
The goal of this interventional investigation is to compare BUFY02 with TRB02 in the treatment of patients with dry eye disease. The main questions it aims to answer are: - Is BUFY02 non-inferior to TRB02 in terms of signs of DED? - Is BUFY02 non-inferior to TRB02 in terms of symptoms of DED? Participants will be asked to: - Visit the trial site at 4 different timepoints - Use the allocated study treatment everyday until the end of the study (during 3 months) - Be examined by the investigator - Complete several questionnaires - Return unused study treatment. Researchers will compare BUFY02 to TRB02 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.
The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are: - Is BUFY01 non-inferior to SVS20 in terms of signs of DED? - Is BUFY01 non-inferior to SVS20 in terms of symptoms of DED? Participants will be asked to: - Visit the trial site at 4 different timepoints - Use the allocated study treatment everyday until the end of the study (during 3 months) - Be examined by the investigator - Complete several questionnaires - Return unused study treatment. Researchers will compare BUFY01 to SVS20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.
The goal of this non-randomized, prospective, open, one-arm clinical study is to learn about the clinical efficacy of stem cell eye drops in patients with dry eye disease (DED) who failed to respond to artificial tear sodium hyaluronate eye drops three times a day for two weeks. The main question aims to answer are: - How effective are stem cell eye drops in patients with DED? - How safe are stem cell eye drops for patients with DED? Participants will be treated with mesenchymal stem cells (MSCs) eye drops, 5×10^5 /50μl in each eye, twice a day for two weeks and they will be followed up for three months after treatment.
The purpose of this clinical trial is to investigate the incidence and magnitude of axial length shortening after repeated low-level red-light therapy in high myopia children and teenagers.
The purpose of this study is to evaluate the preliminary safety and effectiveness of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm
This study aims at demonstrating the non-inferiority of Idroflog compared to sodium hyaluronate 0.18% for the disease improvement of people with documented history of dry eyes and use of tear substitutes for at least 3 months.